Adaptimmune Therapeutics plc held its annual general meeting on May 29, 2025. During the meeting, several proposals were put to a vote. The re-appointment of KPMG LLP as auditors until the next annual general meeting was approved. The authorization for the Audit Committee to determine the auditors' remuneration for the fiscal year ending December 31, 2025, was also approved. Additionally, the adoption of the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2024, with no dividend recommended for that year, was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.